Sun Yuan

専門分野: Pediatric hematologist/oncologist
29年の経験
勤務先: 中国, 北京, Beijing Jingdu Children’s Hospital
As a specialist at the clinic, Professor Sun Yuan is President of Beijing Kyoto Children’s Hospital and a pediatric hematology specialist at Beijing Jingdu Children’s Hospital. She pioneered China’s first autologous cord blood transplant for severe aplastic anemia in 2009. For primary HLH, she pioneered an HSCT timing strategy during the first remission phase, reporting an increase in 5-year survival to 70%–80% from 54% with traditional protocols. Under her leadership, as of May 2025, the hospital had completed nearly 900 HSCT procedures and over 2,000 pediatric congenital heart disease surgeries, and she developed a “1000-Day Post-Transplantation Management Model” including immune reconstruction monitoring starting 3 months post-surgery and early rhGH therapy for growth hormone deficiency.
Professor Sun Yuan is a specialist at the clinic and a pediatric hematology specialist with nearly 30 years of clinical experience. She pioneered China’s first autologous cord blood transplant for severe aplastic anemia (2009) and improved primary HLH outcomes by shifting HSCT to the first remission phase, reporting 5-year survival of 70%–80%. Her differentiator is full-cycle transplant management: she developed a “1000-Day Post-Transplantation Management Model” with immune monitoring starting 3 months after surgery and early rhGH therapy for growth hormone deficiency.

医師のサービス

調子はいかがですか？

1 の 3

この医師の情報は完全で明確です

強く反対

強く賛成

資格

Professor Sun Yuan’s approach to pediatric hematology is built on turning complex immune and transplant problems into a full-cycle plan that continues long after the procedure itself. As a specialist at the clinic, she is a pediatric hematology specialist and currently serves as President of Beijing Kyoto Children’s Hospital. She completed China’s first autologous cord blood transplant for severe aplastic anemia in 2009. For primary HLH, she pioneered an HSCT timing strategy during the first remission phase, reporting 5-year survival increased to 70%–80% from 54% with traditional protocols. Under her leadership, as of May 2025, the hospital had completed nearly 900 HSCT procedures and over 2,000 pediatric congenital heart disease surgeries. She also pioneered a “molecular typing–dynamic monitoring–targeted intervention” system in China, including next-generation sequencing monitoring of minimal residual disease (MRD) after transplantation.

Work experience

President — Beijing Kyoto Children’s Hospital (founding member; established Hematology-Oncology Department in 2015).
Pediatric hematology specialist — Beijing Jingdu Children’s Hospital.

Clinical focus and techniques

Professor Sun Yuan’s clinical focus spans transplant strategies for pediatric hematologic diseases, primary immunodeficiencies, and EB virus–associated hemophagocytic syndromes.

Autologous cord blood transplantation for severe aplastic anemia (completed in 2009).
HSCT for primary HLH with timing during the first remission phase.
“Molecular typing–dynamic monitoring–targeted intervention” system, including next-generation sequencing MRD monitoring after transplantation.
“1000-Day Post-Transplantation Management Model,” including immune reconstruction monitoring starting 3 months post-surgery.
Early rhGH therapy for growth hormone deficiency to prevent short stature.
CD19 CAR-T sequential transplantation for refractory leukemia.
VP-16/BU/FLU/ATG-based reduced-intensity conditioning regimen.

Professional societies and certifications

Pediatrics Branch — Beijing Medical Association.

Academic output

Her profile emphasizes clinical innovation and system-building, including MRD monitoring with next-generation sequencing and transplant outcome improvements reported in her HLH timing strategy.

Courses and advanced training

No named courses or teaching programs are specified in the provided materials.

Awards and recognition

No specific awards are listed in the provided materials.

For international families, the clinic’s transplant pathway includes structured monitoring and longer-term rehabilitation support. Professor Sun Yuan’s work is centered on pediatric hematology and immune system diseases, including HSCT for high-risk, relapsed/refractory conditions and EB virus–associated hemophagocytic syndromes. The clinic also supports online consultation and follow-up planning as part of the post-transplant management model.